$3 million of insider buying @ $33.66. / a 1000%+ increase and 22 Insiders.- PLAY-$35 Dave & Buster's Entertainment, Inc. (PLAY) NasdaqGS - NasdaqGS Real Time Price. 34.99+0.12 (+0.34%) At close: December 23 04:00PM EST
Description Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
DSGN- 1.82 million @$8.41 Insider Buys> 6 insiders. Design Therapeutics, Inc. (DSGN) NasdaqGS - NasdaqGS Real Time Price. $9.53+0.25 (+2.69%)
Design Therapeutics price target lowered to $19 from $26 at Wedbush 12/08 DSGN Wedbush analyst Laura Chico lowered the firm's price target on Design Therapeutics to $19 from $26 and keeps an Outperform rating on the shares. The analyst notes preliminary DT-216 Phase 1 SAD data yielded a 2-fold increase in frataxin mRNA expression but no change in protein expression. The SAD study is a proof-of-mechanism experiment and to that end, Chico does think Design Therapeutics checked the box. Nonetheless, Chico thinks investor expectations may have been "a bit stretched here" given only a single dose was administered. Second, MAD data will include muscle biopsies, but FXN protein expression changes will likely require longer-term DT-216 exposure, she adds. The analyst does think the initial SAD mRNA increases are notable, particularly with uneventful safety; however, it will take time for data to mature.
-->Dec 7 Design Therapeutics' DT-216 phase 1 data looks promising, says Piper Sandler 12/07 DSGN Piper Sandler analyst Yasmeen Rahimi keeps her Overweight rating and $42 price target on Design Therapeutics after the company reported its Phase 1 SAD DT-216 data in Friedreich ataxia, or FA, patients. The stock traded down because of the Street's overly high expectation to show restoration of both mRNA and protein levels after a single dose, the analyst tells investors in a research note. Rahimi adds however that this data provides encouraging signals for DT-216's utility in FA given its ability to affect the underlying cause of the disease, especially as Design Therapeutics continues to explore proper dose finding and longer exposure to optimize the treatment for FA patients.
3 Insider Ideas))))))))))))))))))))))))))))))))))))) 1> MCG (Soho House) 2> Dave & Busters 3> Design Ther- and 1 more... SKIL- $50K @ $1.19